A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Melanoma (Morpheus-Melanoma)
Completed · Phase 1/Phase 2
Conditions studied: Melanoma
In brief
This study will evaluate the efficacy, safety, and pharmacokinetics of treatment combinations in cancer immunotherapy (CIT)-naive participants with resectable Stage III melanoma (Cohort 1) and in participants with Stage IV melanoma (Cohort 2). The study is designed with the flexibility to open new treatment arms as new treatments become available, close existing treatment arms that demonstrate minimal clinical activity or unacceptable toxicity, and modify the participant population.
Key facts
- Study ID
- NCT05116202
- Run by
- Hoffmann-La Roche
- People needed
- 110
- Starts
- 2022-02-02
- Expected to finish
- 2024-05-28
- Last updated by the study team
- 2025-07-18
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- City of Hope — Duarte, California, United States
- The Angeles Clinic and Research Institute - W LA Office — Los Angeles, California, United States
- Moffitt Cancer Center — Tampa, Florida, United States
- MD Anderson Cancer Center — Houston, Texas, United States
- Melanoma Institute Australia — North Sydney, New South Wales, Australia
- Hopital de la Timone — Marseille, France
- APHP - Hospital Saint Louis — Paris, France
- Institut Universitaire du Cancer de Toulouse-Oncopole — Toulouse, France
- Institut Gustave Roussy — Villejuif, France
- Azienda Ospedaliera Universitaria Senese — Siena, Abruzzo, Italy
- Istituto Nazionale Tumori Fondazione G. Pascale — Naples, Campania, Italy
- Istituto Europeo Di Oncologia — Milan, Lombardy, Italy
- Ospedale S.Maria della Misericordia — Perugia, Umbria, Italy
- Hospital Universitario Vall d Hebron — Barcelona, Spain
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.